Hi Plotinus.
We already know what the poster would have said. It would have said exactly what was told us in the December 2024 Letter To Shareholders
Maybe the poster would have included the p-values and exactly what the confidence intervals were, but for the most part, we already know what the poster would have said and what the presentation would have communicated.
Neither the presentation nor the poster would discuss the findings of the 2 follow up studies which were introduced in that same Letter to Shareholders:
The results of these 2 follow up studies are what we await in January.
We already know what the poster would have said. It would have said exactly what was told us in the December 2024 Letter To Shareholders
Quote:
"First, CytoDyn previously announced exciting results from an initial preclinical study with SMC Laboratories evaluating leronlimab in the treatment of a mouse model of MASH. The results from this preliminary study demonstrated that high dose leronlimab was significantly better at reversing liver fibrosis compared to an IgG 4 isotype control and demonstrated a trend toward better fibrosis reversal compared to Resmetirom. The final results from that study have now also demonstrated that leronlimab (both high and low dose) was significantly better than Resmetirom at reversal of fat deposition (steatosis) in the liver. These exciting findings have been submitted as a late breaker abstract to the MASH TAG conference and, if accepted, will be presented at the meeting in January . "
Maybe the poster would have included the p-values and exactly what the confidence intervals were, but for the most part, we already know what the poster would have said and what the presentation would have communicated.
Neither the presentation nor the poster would discuss the findings of the 2 follow up studies which were introduced in that same Letter to Shareholders:
Quote:
"In September, CytoDyn launched two follow up studies to confirm and expand on these preliminary results. The first follow-up study seeks to confirm the observations of the original study with larger cohorts of mice (12 versus the original 8/group) and will compare leronlimab with a GLP-1 agonist (Semaglutide) in addition to confirming the comparisons with Resmetirom. The second follow-up study involves the administration of CCL4, a drug that directly causes liver fibrosis in mice. This study will clarify if the observed reversal of liver fibrosis is restricted to the MASH/fat deposition pathway or might occur independently of the etiology of fibrosis (e.g. alcohol, viral hepatitis, etc.) . The results from both follow-up studies will become available in January . As a side note, we have been contacted by colleagues at a major academic institution who indicated that, if the liver fibrosis reversal results are confirmed in the follow-up studies, they would be interested in funding a pilot study of leronlimab in the treatment of patients with pulmonary fibrosis at their own center ."
The results of these 2 follow up studies are what we await in January.
15
